Deutsche Bank AG Sells 121,601 Shares of Denali Therapeutics Inc. $DNLI

Key Points

• Deutsche Bank AG reduced its stake in Denali Therapeutics by 43.8%, now owning approximately 156,252 shares valued at $2.12 million.
• Multiple hedge funds have increased their holdings in Denali Therapeutics, with Polar Asset Management Partners Inc. raising their stake by an exceptional 1,240.9% in the last quarter.
• Analysts have offered mixed ratings on Denali’s stock, with a consensus rating of "Buy" and a target price averaging $33.62.

Deutsche Bank AG lessened its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 43.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,252 shares of the company's stock after selling 121,601 shares during the quarter. Deutsche Bank AG owned approximately 0.11% of Denali Therapeutics worth $2,125,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Denali Therapeutics by 6.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock worth $62,335,000 after buying an additional 188,820 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock valued at $37,805,000 after purchasing an additional 295,594 shares in the last quarter. Northern Trust Corp raised its stake in Denali Therapeutics by 10.7% during the fourth quarter. Northern Trust Corp now owns 1,201,518 shares of the company's stock valued at $24,487,000 after purchasing an additional 115,876 shares in the last quarter. Stempoint Capital LP raised its stake in Denali Therapeutics by 107.2% during the fourth quarter. Stempoint Capital LP now owns 584,328 shares of the company's stock valued at $11,909,000 after purchasing an additional 302,278 shares in the last quarter. Finally, Polar Asset Management Partners Inc. raised its stake in Denali Therapeutics by 1,240.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company's stock valued at $11,231,000 after purchasing an additional 509,992 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Trading Down 0.1%

Shares of NASDAQ DNLI traded down $0.02 during mid-day trading on Tuesday, reaching $15.55. The company had a trading volume of 2,024,184 shares, compared to its average volume of 1,817,729. The business's 50-day moving average is $14.36 and its 200-day moving average is $14.93. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -5.55 and a beta of 1.36. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the prior year, the firm earned ($0.59) earnings per share. Equities analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 2,937 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 242,346 shares in the company, valued at approximately $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 501,962 shares of company stock worth $7,520,799. Insiders own 12.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DNLI shares. Wedbush decreased their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Bank of America decreased their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Morgan Stanley decreased their price target on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a research note on Monday, August 18th. Finally, HC Wainwright decreased their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.